These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9013817)

  • 1. Relationship between the metabolic chiral inversion and chemical structure of 4-phenyl-4-oxobutanoic acids, derivatives of anti-rheumatic agent KE-298.
    Yoshida H; Kohno Y; Endo H; Fukushima K; Suwa T; Hayashi M
    Biol Pharm Bull; 1997 Jan; 20(1):94-6. PubMed ID: 9013817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic studies on metabolic chiral inversion of 4-(4-methylphenyl)-2-methylthiomethyl-4-oxobutanoic acid (KE-748), an active metabolite of the new anti-rheumatic agent 2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298), in rats.
    Yoshida H; Kohno Y; Endo H; Yamaguchi J; Fukushima K; Suwa T; Hayashi M
    Biochem Pharmacol; 1997 Jan; 53(2):179-87. PubMed ID: 9037250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and antirheumatic activity of optically active 2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298).
    Kameo K; Takeshita K; Yasuda Y; Matsumoto K; Tomisawa K
    Chem Pharm Bull (Tokyo); 1996 Mar; 44(3):602-4. PubMed ID: 8882457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A practical procedure for the synthesis of esonarimod, (R,S)-2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid, an antirheumatic agent (part 1).
    Noguchi T; Onodera A; Tomisawa K; Yokomori S
    Chem Pharm Bull (Tokyo); 2002 Oct; 50(10):1407-12. PubMed ID: 12372877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective disposition and chiral inversion of KE-298, a new antirheumatic drug, in rats.
    Yoshida H; Kohno Y; Endo H; Ohmi N; Fukushima K; Suwa T; Hayashi M
    Chirality; 1997; 9(1):22-8. PubMed ID: 9094199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective pharmacokinetics of [14C]-labeled KE-298, a new anti-rheumatic drug, in rats.
    Yoshida H; Kohno Y; Endo H; Hasegawa M; Suwa T
    Chirality; 1996; 8(3):258-63. PubMed ID: 8777146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formation of a disulfide protein conjugate of the SH-group-containing metabolite (M-I) of esonarimod (KE-298) and its elimination in rats.
    Hasegawa M; Omi N; Endo H; Yoshida H; Higuchi S
    J Pharm Pharmacol; 2002 Apr; 54(4):493-8. PubMed ID: 11999126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antirheumatic activity of the metabolites of esonarimod.
    Noguchi T; Onodera A; Tomisawa K; Yamashita M; Takeshita K; Yokomori S
    Bioorg Med Chem; 2002 Aug; 10(8):2713-21. PubMed ID: 12057660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of KE-758, the main metabolite of the antirheumatic agent KE-298.
    Yasuda Y; Inoue T; Takeshita K
    Drugs Exp Clin Res; 1996; 22(1):1-8. PubMed ID: 8839631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New disease-modifying antirheumatic drug 2 acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid (KE-298) selectively augments activation-induced T cell death.
    Urayama S; Kawakami A; Nakashima T; Yamasaki S; Hida A; Ida H; Kamachi M; Nakamura H; Origuchi T; Migita K; Kawabe Y; Eguchi K
    J Lab Clin Med; 2001 Jul; 138(1):11-7. PubMed ID: 11433223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of glycine conjugate and (-)-(R)-enantiomer from (+)-(S)-2-phenylpropionic acid suggesting the formation of the CoA thioester intermediate of (+)-(S)-enantiomer in dogs.
    Tanaka Y; Shimomura Y; Hirota T; Nozaki A; Ebata M; Takasaki W; Shigehara E; Hayashi R; Caldwell J
    Chirality; 1992; 4(6):342-8. PubMed ID: 1449948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereospecific taurine conjugation of the trans-OH metabolite (active metabolite) of CS-670, a new 2-arylpropionic acid nonsteroidal anti-inflammatory drug, in dogs.
    Asami M; Takasaki W; Iwabuchi H; Haruyama H; Wachi K; Terada A; Tanaka Y
    Biol Pharm Bull; 1995 Nov; 18(11):1584-9. PubMed ID: 8593485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences.
    Caldwell J; Hutt AJ; Fournel-Gigleux S
    Biochem Pharmacol; 1988 Jan; 37(1):105-14. PubMed ID: 3276314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mechanistic investigation of the microbial chiral inversion of 2-phenylpropionic acid by Verticillium lecanii.
    Thomason MJ; Rhys-Williams W; Hung YF; Baker JA; Hanlon GW; Lloyd AW
    Chirality; 1997; 9(3):254-60. PubMed ID: 9176991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of the chiral inversion of 2-phenylpropionic acid by Verticillium lecanii.
    Thomason MJ; Rhys-Williams W; Lloyd AW; Hanlon GW
    J Pharm Pharmacol; 1997 Mar; 49(3):263-9. PubMed ID: 9231342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbial metabolism of 2-arylpropionic acids: chiral inversion of ibuprofen and 2-phenylpropionic acid.
    Hutt AJ; Kooloobandi A; Hanlon GW
    Chirality; 1993; 5(8):596-601. PubMed ID: 8305287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a new anti-rheumatic drug KE-298 and its active metabolite: KE-758 on secretion of thioredoxin and on the level of intracellular glutathione in human monocytes and T cells.
    Sugimoto M; Inoue T; Takeshita K; Nakamura H; Yodoi J
    Mol Immunol; 2002 Feb; 38(10):793-9. PubMed ID: 11841839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereoselective determination of the active metabolites of a new anti-inflammatory agent (CS-670) in human and rat plasma using antibody-mediated extraction and high-performance liquid chromatography.
    Takasaki W; Asami M; Muramatsu S; Hayashi R; Tanaka Y; Kawabata K; Hoshiyama K
    J Chromatogr; 1993 Mar; 613(1):67-77. PubMed ID: 8458904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo studies on chiral inversion and amino acid conjugation of 2-[4-(3-methyl-2-thienyl)phenyl]propionic acid in rats and dogs.
    Konishi T; Nishikawa H; Kitamura S; Tatsumi K
    Drug Metab Dispos; 1999 Jan; 27(1):158-60. PubMed ID: 9884325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic chiral inversion of 2-phenylpropionic acid in rat, mouse and rabbit.
    Fournel S; Caldwell J
    Biochem Pharmacol; 1986 Dec; 35(23):4153-9. PubMed ID: 3790146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.